Sunday, November, 27, 2022 08:52:15
Co-Diagnostics, Inc. announces the launch of Vector Smart™ NAM test
the company which develops molecular diagnostic tests with its patented platform has announced the product launch of its Vector Smart™ NAM test. The test will be used to detect pathogens like St. Louis encephalitis, West Nile virus and western equine encephalitis across the mosquito affected populations.
Migratory birds and other parasites are responsible for carrying deadly pathogens like West Nile virus across continents, post which they are locally transmitted to humans or livestock through mosquitoes. The rising mosquito population is usually controlled via mosquito abatement districts though the application of pesticide and non-pesticide-based treatment methods.
Recently a report stated that the United States professional pest control industry has accrued nearly $9 billion in 2018. The mosquito control services segment of this domain is one of the fastest growing segments, apparently.
Dwight Egan, Co-Diagnostics CEO passed a remark over the company’s CoPrimer™-based North American mosquito test, claiming that it is the first multiplex polymerase chain reaction (PCR) test of its kind and has a target market of over 1,000 mosquito affected districts across the continent. This highly accurate PCR test will help the disease control centers to identify infectious diseases and thereby work on stopping them from spreading further, Egan continued.
He also added that in addition to be the only multiplex test available today, no existing single-plex products or any similar of its kind can match the accuracy provided by it. The test is already on sales since the second quarter of 2019 and is expected to continually increase.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah based corporation, is a molecular diagnostics company renowned for its state-of-the-art diagnostics technology, which focuses on analyzing the nucleic acid molecules (DNA or RNA). The firm also designs tests to locate genetic markers for a specific infectious disease and licenses the use of those tests to specific customers only.